P
Prudence Kgagudi
Researcher at National Health Laboratory Service
Publications - 24
Citations - 1913
Prudence Kgagudi is an academic researcher from National Health Laboratory Service. The author has contributed to research in topics: Antibody & Neutralization. The author has an hindex of 9, co-authored 14 publications receiving 857 citations. Previous affiliations of Prudence Kgagudi include National Research Foundation of South Africa & University of the Witwatersrand.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
Constantinos Kurt Wibmer,Frances Ayres,Tandile Hermanus,Mashudu Madzivhandila,Prudence Kgagudi,Brent Oosthuysen,Bronwen E. Lambson,Bronwen E. Lambson,Tulio de Oliveira,Marion Vermeulen,Karin van der Berg,Karin van der Berg,Theresa M. Rossouw,Michael T. Boswell,Veronica Ueckermann,Susan Meiring,Anne von Gottberg,Anne von Gottberg,Cheryl Cohen,Cheryl Cohen,Lynn Morris,Lynn Morris,Jinal N. Bhiman,Jinal N. Bhiman,Penny L. Moore,Penny L. Moore +25 more
TL;DR: In this article, the authors show that SARS-CoV-2 501Y.1.V2 spike protein completely escapes three classes of therapeutically relevant antibodies and exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma.
Posted ContentDOI
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer,Frances Ayres,Tandile Hermanus,Mashudu Madzivhandila,Prudence Kgagudi,Brent Oosthuysen,Bronwen E. Lambson,Bronwen E. Lambson,Tulio de Oliveira,Marion Vermeulen,Karin van der Berg,Karin van der Berg,Theresa M. Rossouw,Michael T. Boswell,Veronica Ueckermann,Susan Meiring,Anne von Gottberg,Anne von Gottberg,Cheryl Cohen,Cheryl Cohen,Lynn Morris,Lynn Morris,Jinal N. Bhiman,Jinal N. Bhiman,Penny L. Moore,Penny L. Moore +25 more
TL;DR: SARS-CoV-2 501Y.V2 (B.1.351), a lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein this article.
Journal ArticleDOI
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
Lingshu Wang,Tongqing Zhou,Yi Zhang,Eun Sung Yang,Chaim A. Schramm,Wei Shi,Amarendra Pegu,Olamide K. Oloniniyi,Amy R. Henry,Samuel Darko,Sandeep Narpala,Christian Hatcher,David R. Martinez,Yaroslav Tsybovsky,Emily Phung,Olubukola M. Abiona,Avan Antia,Evan M. Cale,Lauren A. Chang,Misook Choe,Kizzmekia S. Corbett,Rachel L. Davis,Anthony T. DiPiazza,Ingelise J. Gordon,Sabrina Helmold Hait,Tandile Hermanus,Tandile Hermanus,Prudence Kgagudi,Prudence Kgagudi,Farida Laboune,Kwanyee Leung,Tracy Liu,Rosemarie D. Mason,Alexandra Nazzari,Laura Novik,Sarah O’Connell,Sijy O'Dell,Adam S. Olia,Stephen D. Schmidt,Tyler Stephens,Christopher D. Stringham,Chloe Adrienna Talana,I-Ting Teng,Danielle A. Wagner,Alicia T. Widge,Baoshan Zhang,Mario Roederer,Julie E. Ledgerwood,Tracy J. Ruckwardt,Martin R. Gaudinski,Penny L. Moore,Penny L. Moore,Nicole A. Doria-Rose,Ralph S. Baric,Barney S. Graham,Adrian B. McDermott,Daniel C. Douek,Peter D. Kwong,John R. Mascola,Nancy J. Sullivan,John Misasi +60 more
TL;DR: This paper identified four receptor binding domain-targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 23 variants of SARS-CoV-2 variants of concern (VOCs).
Journal ArticleDOI
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Shabir A. Madhi,Shabir A. Madhi,Anthonet Koen,Anthonet Koen,Alane Izu,Alane Izu,Lee Fairlie,Clare L. Cutland,Vicky L. Baillie,Vicky L. Baillie,S D Padayachee,Keertan Dheda,Keertan Dheda,Shaun Barnabas,Q E Bhorat,Carmen Briner,Parvinder K. Aley,Sutika Bhikha,Sutika Bhikha,Tandile Hermanus,Tandile Hermanus,Elizea Horne,Aylin Jose,Aylin Jose,Prudence Kgagudi,Prudence Kgagudi,Teresa Lambe,Masebole Masenya,Mduduzi Masilela,Nonhlanhla N. Mkhize,Nonhlanhla N. Mkhize,Andrew Moultrie,Andrew Moultrie,Christian Kabasele Mukendi,Christian Kabasele Mukendi,Thandeka Moyo-Gwete,Thandeka Moyo-Gwete,Amit J Nana,Amit J Nana,Ayanda Nzimande,Ayanda Nzimande,Faeezah Patel,S Rhead,Carol Taoushanis,Carol Taoushanis,Asha Thombrayil,Asha Thombrayil,Samuel van Eck,Merryn Voysey,Tonya Villafana,Johan Vekemans,Sarah C. Gilbert,Andrew J. Pollard,Penny L. Moore,Penny L. Moore,Gaurav Kwatra,Gaurav Kwatra +56 more
TL;DR: In this article, the safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people living with HIV and HIV-negative individuals in South Africa were evaluated.
Journal ArticleDOI
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Thandeka Moyo-Gwete,Mashudu Madzivhandila,Zanele Makhado,Frances Ayres,Donald Mhlanga,Brent Oosthuysen,Bronwen E. Lambson,Prudence Kgagudi,Houriiyah Tegally,Arash Iranzadeh,Deelan Doolabh,Lynn Tyers,Lionel Chinhoyi,Mathilda Mennen,Sango Skelem,Gert Marais,Constantinos Kurt Wibmer,Jinal N. Bhiman,Veronica Ueckermann,Theresa M. Rossouw,Michael T. Boswell,Tulio de Oliveira,Carolyn Williamson,Wendy A. Burgers,Ntobeko A B Ntusi,Lynn Morris,Penny L. Moore +26 more
TL;DR: Cross-Reactive Antibody Responses Elicited by the 501Y.V2 Variant Convalescent serum from persons who had recovered from infection with B.1.351, a SARS-CoV-2 variant first identified in SARS as discussed by the authors.